Meningococcal Disease
📧 Sign up to get email alerts when something new happens for Meningococcal Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-11-04Clinical Trial Update: Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial assessing safety, tolerability, and immunogenicity of Novartis' recombinant meningococcal B vaccine in heal…
-
CLINICAL_TRIALS trial_result · 2015-08-06Clinical Trial Update: Safety Surveillance of MenACWY-CRM Vaccine in Children
A completed safety surveillance update for the MenACWY-CRM meningococcal vaccine in children is reported.
-
CLINICAL_TRIALS trial_result · 2015-06-04Clinical Trial Update: A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years [Phase 2]
Phase 2 trial assessing safety, tolerability, and immunogenicity of the Rlp2086 vaccine in two- or three-dose regimens in healthy adolescent…
-
CLINICAL_TRIALS trial_result · 2015-05-25Clinical Trial Update: A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, and immunogenic response of MCV4, Tdap, and Bivalent rLP2086 vaccine co-administered…
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®) [Phase 3]
Pfizer completed a Phase 3 safety and immunogenicity study of NeisVac-C (meningococcal serogroup C conjugate vaccine) in toddlers previously…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: NeisVac-C Single Prime Study in Infants [Phase 3]
Pfizer's NeisVac-C single-prime Phase 3 trial in infants has completed.
-
CLINICAL_TRIALS trial_result · 2015-04-14Clinical Trial Update: A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents [Phase 2]
Phase 2 trial evaluating safety and immunogenicity of the meningococcal B vaccine RLP2086 in adolescents has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2015-04-10Clinical Trial Update: One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age [Phase 3]
Phase 3 trial evaluating long-term antibody persistence after booster dosing schedules of the Novartis Meningococcal B Recombinant Vaccine i…
-
CLINICAL_TRIALS trial_result · 2015-03-11Clinical Trial Update: A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years [Phase 3]
Pfizer completed a global Phase 3 safety study of a 120 mcg rLP2086 vaccine in adolescents and young adults (ages 10-25); results were poste…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. [Phase 3]
Phase 3 trial update reporting safety and immunogenicity results for two doses of the Novartis meningococcal B recombinant vaccine in adoles…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants [Phase 2]
Phase 2 trial evaluating safety, tolerability, and immunogenicity of two formulations of a meningococcal B recombinant vaccine in healthy in…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults [Phase 3]
This update reports the completion of a Phase 3b study assessing the safety of the Novartis Meningococcal B Recombinant Vaccine in healthy a…
-
CLINICAL_TRIALS trial_result · 2015-03-03Clinical Trial Update: Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers [Phase 3]
Extension Phase 3 trial evaluating the safety, tolerability, and immunogenicity of the Novartis meningococcal B recombinant vaccine when adm…
-
CLINICAL_TRIALS trial_result · 2015-02-26Clinical Trial Update: Safety of MenACWY-CRM Vaccination in Adolescents
This clinical trial update summarizes safety findings for the MenACWY-CRM meningococcal conjugate vaccine in adolescents.
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years [Phase 3]
Phase 3 trial assessing safety and immunogenicity of Novartis Meningococcal B Vaccine (OMV-based) in healthy adolescents aged 11-17, with fo…
-
CLINICAL_TRIALS trial_result · 2015-02-12Clinical Trial Update: 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds
36-month post-marketing surveillance of Menactra in 2-10 year olds was completed, with results posted. The study assessed safety and effecti…
-
CLINICAL_TRIALS trial_result · 2015-01-13Clinical Trial Update: Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 [Phase 3]
Phase 3 trial evaluating persistence of antibodies and vaccine response to the meningococcal B recombinant vaccine in 4-year-old children; r…
-
CLINICAL_TRIALS trial_result · 2014-11-26Clinical Trial Update: A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. [Phase 2]
Phase 2 trial evaluating safety, tolerability, and immunogenicity of Repevax and rLP2086 vaccine given together in adolescents aged 11 to <1…
-
CLINICAL_TRIALS trial_result · 2014-11-19Clinical Trial Update: Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines [Phase 2]
Phase 2 trial assessing safety, tolerability, and immunogenicity of a third dose of four formulations of an rMenB + MenACWY meningococcal va…
-
CLINICAL_TRIALS trial_result · 2014-11-14Clinical Trial Update: Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines [Phase 4]
Phase 4 post-marketing safety study of Menactra meningococcal vaccine conducted in healthy children, adolescents, and adults in the Philippi…
-
CLINICAL_TRIALS trial_result · 2014-11-11Clinical Trial Update: Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine
This document reports on a descriptive, post-marketing safety study of the Menactra meningococcal conjugate vaccine, conducted by Sanofi Pas…
-
CLINICAL_TRIALS trial_result · 2014-10-31Clinical Trial Update: A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. [Phase 3]
Phase 3b open-label trial evaluating immunogenicity and safety of Novartis Meningococcal B Recombinant Vaccine given on a 0, 2-month schedul…
-
CLINICAL_TRIALS trial_result · 2014-10-29Clinical Trial Update: Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines [Phase 1, Phase 2]
This clinical trial update reports dose-finding and safety data from two intradermal MEN-ACYW135-conjugate vaccines evaluated in Phase 1/2 f…
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. [Phase 3]
Phase 3 trial assessing immunogenicity, safety, and 1-year persistence of antibodies after one or two doses of a meningococcal ACWY conjugat…
-
CLINICAL_TRIALS trial_result · 2014-10-02Clinical Trial Update: Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life [Phase 3]
Phase 3 clinical trial evaluating safety and immunogenicity of 2 or 3 doses of a MenACWY conjugate vaccine in healthy infants and the effect…